- Home
- FTDR vs AKRO Comparison
FTDR vs AKRO Comparison
Compare FTDR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- AKRO
- Stock Information
- Founded
- FTDR 1971
- AKRO 2017
- Country
- FTDR United States
- AKRO United States
- Employees
- FTDR N/A
- AKRO N/A
- Industry
- FTDR Diversified Commercial Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- AKRO Health Care
- Exchange
- FTDR Nasdaq
- AKRO Nasdaq
- Market Cap
- FTDR 4.4B
- AKRO 3.6B
- IPO Year
- FTDR 2018
- AKRO 2019
- Fundamental
- Price
- FTDR $66.66
- AKRO $43.73
- Analyst Decision
- FTDR Hold
- AKRO Strong Buy
- Analyst Count
- FTDR 4
- AKRO 8
- Target Price
- FTDR $59.75
- AKRO $80.38
- AVG Volume (30 Days)
- FTDR 639.7K
- AKRO 923.5K
- Earning Date
- FTDR 11-03-2025
- AKRO 11-07-2025
- Dividend Yield
- FTDR N/A
- AKRO N/A
- EPS Growth
- FTDR 29.61
- AKRO N/A
- EPS
- FTDR 3.36
- AKRO N/A
- Revenue
- FTDR $1,966,000,000.00
- AKRO N/A
- Revenue This Year
- FTDR $14.54
- AKRO N/A
- Revenue Next Year
- FTDR $6.49
- AKRO N/A
- P/E Ratio
- FTDR $20.00
- AKRO N/A
- Revenue Growth
- FTDR 8.62
- AKRO N/A
- 52 Week Low
- FTDR $35.61
- AKRO $21.34
- 52 Week High
- FTDR $67.23
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- FTDR 68.25
- AKRO 37.54
- Support Level
- FTDR $63.31
- AKRO $42.56
- Resistance Level
- FTDR $67.26
- AKRO $46.18
- Average True Range (ATR)
- FTDR 2.00
- AKRO 1.80
- MACD
- FTDR 0.51
- AKRO -0.17
- Stochastic Oscillator
- FTDR 95.23
- AKRO 17.12
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.